Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04431635
Title Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Big Ten Cancer Research Consortium
Indications

follicular lymphoma

marginal zone B-cell lymphoma

Therapies

Copanlisib + Nivolumab + Rituximab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.